Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib + TAS-102 in Metastatic Colorectal Cancer
NCT03305913Phase 1Completed
- Sponsor
- AIO-Studien
- Start
- Jul 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of trifluridine + tipiracil and regorafenib in metastatic colorectal cancer (mCRC) (6 arms), sponsored by AIO-Studien. Primary endpoint: Maximum Tolerated Dose at 2 months. Started Jul 2017; status: completed.
02
Drugs
trifluridine + tipiracilregorafenib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03305913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305913.